Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Combined cerebral atrophy score in Huntington's disease based on atlas-based MRI volumetry: Sample size calculations for clinical trials.

Müller HP, Huppertz HJ, Dreyhaupt J, Ludolph AC, Tabrizi SJ, Roos RAC, Durr A, Landwehrmeyer GB, Kassubek J.

Parkinsonism Relat Disord. 2019 Feb 5. pii: S1353-8020(19)30035-5. doi: 10.1016/j.parkreldis.2019.02.004. [Epub ahead of print]

PMID:
30846243
2.

Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials.

Höglinger GU, Schöpe J, Stamelou M, Kassubek J, Del Ser T, Boxer AL, Wagenpfeil S, Huppertz HJ; AL-108-231 Investigators; Tauros MRI Investigators; Movement Disorder Society-Endorsed PSP Study Group.

Mov Disord. 2017 Jun;32(6):842-852. doi: 10.1002/mds.26973. Epub 2017 Apr 24.

3.

Early atrophy of pallidum and accumbens nucleus in Huntington's disease.

van den Bogaard SJ, Dumas EM, Acharya TP, Johnson H, Langbehn DR, Scahill RI, Tabrizi SJ, van Buchem MA, van der Grond J, Roos RA; TRACK-HD Investigator Group.

J Neurol. 2011 Mar;258(3):412-20. doi: 10.1007/s00415-010-5768-0. Epub 2010 Oct 9.

4.

Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.

Tabrizi SJ, Reilmann R, Roos RA, Durr A, Leavitt B, Owen G, Jones R, Johnson H, Craufurd D, Hicks SL, Kennard C, Landwehrmeyer B, Stout JC, Borowsky B, Scahill RI, Frost C, Langbehn DR; TRACK-HD investigators.

Lancet Neurol. 2012 Jan;11(1):42-53. doi: 10.1016/S1474-4422(11)70263-0. Epub 2011 Dec 2.

PMID:
22137354
5.

Basal ganglia atrophy in prodromal Huntington's disease is detectable over one year using automated segmentation.

Majid DS, Aron AR, Thompson W, Sheldon S, Hamza S, Stoffers D, Holland D, Goldstein J, Corey-Bloom J, Dale AM.

Mov Disord. 2011 Dec;26(14):2544-51. doi: 10.1002/mds.23912. Epub 2011 Sep 19.

6.

Mapping the order and pattern of brain structural MRI changes using change-point analysis in premanifest Huntington's disease.

Wu D, Faria AV, Younes L, Mori S, Brown T, Johnson H, Paulsen JS, Ross CA, Miller MI; PREDICT-HD Investigators and Coordinators of the Huntington Study Group.

Hum Brain Mapp. 2017 Oct;38(10):5035-5050. doi: 10.1002/hbm.23713. Epub 2017 Jun 28.

7.

The progression of regional atrophy in premanifest and early Huntington's disease: a longitudinal voxel-based morphometry study.

Hobbs NZ, Henley SM, Ridgway GR, Wild EJ, Barker RA, Scahill RI, Barnes J, Fox NC, Tabrizi SJ.

J Neurol Neurosurg Psychiatry. 2010 Jul;81(7):756-63. doi: 10.1136/jnnp.2009.190702. Epub 2009 Dec 1.

PMID:
19955112
8.

Striatal morphology correlates with frontostriatal electrophysiological motor processing in Huntington's disease: an IMAGE-HD study.

Turner LM, Jakabek D, Wilkes FA, Croft RJ, Churchyard A, Walterfang M, Velakoulis D, Looi JC, Georgiou-Karistianis N, Apthorp D.

Brain Behav. 2016 Jul 27;6(12):e00511. doi: 10.1002/brb3.511. eCollection 2016 Dec.

9.

Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study.

Peinemann A, Schuller S, Pohl C, Jahn T, Weindl A, Kassubek J.

J Neurol Sci. 2005 Dec 15;239(1):11-9. Epub 2005 Sep 26.

PMID:
16185716
10.

Elevated brain iron is independent from atrophy in Huntington's Disease.

Dumas EM, Versluis MJ, van den Bogaard SJ, van Osch MJ, Hart EP, van Roon-Mom WM, van Buchem MA, Webb AG, van der Grond J, Roos RA; TRACK-HD investigators.

Neuroimage. 2012 Jul 2;61(3):558-64. doi: 10.1016/j.neuroimage.2012.03.056. Epub 2012 Mar 28.

PMID:
22480728
11.

Design optimization for clinical trials in early-stage manifest Huntington's disease.

Frost C, Mulick A, Scahill RI, Owen G, Aylward E, Leavitt BR, Durr A, Roos RAC, Borowsky B, Stout JC, Reilmann R, Langbehn DR, Tabrizi SJ, Sampaio C; TRACK-HD Investigators.

Mov Disord. 2017 Nov;32(11):1610-1619. doi: 10.1002/mds.27122. Epub 2017 Sep 14.

12.

Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis.

Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R, Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL, Kennard C, Craufurd D, Frost C, Langbehn DR, Reilmann R, Stout JC; TRACK-HD Investigators.

Lancet Neurol. 2011 Jan;10(1):31-42. doi: 10.1016/S1474-4422(10)70276-3. Epub 2010 Dec 2.

PMID:
21130037
13.

Multimodal imaging biomarkers in premanifest and early Huntington's disease: 30-month IMAGE-HD data.

D JF, Stout JC, Poudel G, Churchyard A, Chua P, Egan GF, Georgiou-Karistianis N.

Br J Psychiatry. 2016 Jun;208(6):571-8. doi: 10.1192/bjp.bp.114.156588. Epub 2015 Dec 17.

PMID:
26678864
14.

Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease.

Harris GJ, Pearlson GD, Peyser CE, Aylward EH, Roberts J, Barta PE, Chase GA, Folstein SE.

Ann Neurol. 1992 Jan;31(1):69-75.

PMID:
1531910
15.

Shape analysis of subcortical nuclei in Huntington's disease, global versus local atrophy--results from the TRACK-HD study.

van den Bogaard SJ, Dumas EM, Ferrarini L, Milles J, van Buchem MA, van der Grond J, Roos RA.

J Neurol Sci. 2011 Aug 15;307(1-2):60-8. doi: 10.1016/j.jns.2011.05.015. Epub 2011 May 31.

16.

White matter integrity in premanifest and early Huntington's disease is related to caudate loss and disease progression.

Novak MJ, Seunarine KK, Gibbard CR, Hobbs NZ, Scahill RI, Clark CA, Tabrizi SJ.

Cortex. 2014 Mar;52:98-112. doi: 10.1016/j.cortex.2013.11.009. Epub 2013 Dec 6.

PMID:
24405816
17.

Fully automated atlas-based MR imaging volumetry in Huntington disease, compared with manual volumetry.

Kassubek J, Pinkhardt EH, Dietmaier A, Ludolph AC, Landwehrmeyer GB, Huppertz HJ.

AJNR Am J Neuroradiol. 2011 Aug;32(7):1328-32. doi: 10.3174/ajnr.A2514. Epub 2011 Jun 16.

18.

Progression of structural neuropathology in preclinical Huntington's disease: a tensor based morphometry study.

Kipps CM, Duggins AJ, Mahant N, Gomes L, Ashburner J, McCusker EA.

J Neurol Neurosurg Psychiatry. 2005 May;76(5):650-5.

19.

Atrophy of the putamen at time of clinical motor onset in Huntington's disease: a 6-year follow-up study.

Coppen EM, van der Grond J, Roos RAC.

J Clin Mov Disord. 2018 Mar 23;5:2. doi: 10.1186/s40734-018-0069-3. eCollection 2018.

20.

Grey matter volume loss is associated with specific clinical motor signs in Huntington's disease.

Coppen EM, Jacobs M, van den Berg-Huysmans AA, van der Grond J, Roos RAC.

Parkinsonism Relat Disord. 2018 Jan;46:56-61. doi: 10.1016/j.parkreldis.2017.11.001. Epub 2017 Nov 2.

PMID:
29128164

Supplemental Content

Support Center